IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the Swedish Medical Products Agency has approved the initiation of a Phase I clinical study of the drug candidate IRL757.
IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the Swedish Medical Products Agency has approved the initiation of a Phase I clinical study of the drug candidate IRL757.